1256 related articles for article (PubMed ID: 23229955)
21. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
[TBL] [Abstract][Full Text] [Related]
22. E1A- and E1B-Double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects.
Kim J; Kim JH; Choi KJ; Kim PH; Yun CO
Hum Gene Ther; 2007 Sep; 18(9):773-86. PubMed ID: 17725410
[TBL] [Abstract][Full Text] [Related]
23. Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus.
Zhou W; Zhu H; Chen W; Hu X; Pang X; Zhang J; Huang X; Fang B; He C
Cancer Gene Ther; 2011 May; 18(5):336-45. PubMed ID: 21183948
[TBL] [Abstract][Full Text] [Related]
24. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
[TBL] [Abstract][Full Text] [Related]
25. Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells.
Watanabe Y; Hashimoto Y; Kagawa S; Kawamura H; Nagai K; Tanaka N; Urata Y; Fujiwara T
Cancer Gene Ther; 2012 Nov; 19(11):767-72. PubMed ID: 22956040
[TBL] [Abstract][Full Text] [Related]
26. Complete eradication of hepatomas using an oncolytic adenovirus containing AFP promoter controlling E1A and an E1B deletion to drive IL-24 expression.
Zhang KJ; Zhang J; Wu YM; Qian J; Liu XJ; Yan LC; Zhou XM; Xiao RJ; Wang YG; Cao X; Wei N; Liu XR; Tang B; Jiao XY; Chen K; Liu XY
Cancer Gene Ther; 2012 Sep; 19(9):619-29. PubMed ID: 22790965
[TBL] [Abstract][Full Text] [Related]
27. Control of E1A under an E2F-1 promoter insulated with the myotonic dystrophy locus insulator reduces the toxicity of oncolytic adenovirus Ad-Delta24RGD.
Majem M; Cascallo M; Bayo-Puxan N; Mesia R; Germa JR; Alemany R
Cancer Gene Ther; 2006 Jul; 13(7):696-705. PubMed ID: 16498429
[TBL] [Abstract][Full Text] [Related]
28. Preclinical pharmacology and toxicology study of Ad-hTERT-E1a-Apoptin, a novel dual cancer-specific oncolytic adenovirus.
Qi Y; Guo H; Hu N; He D; Zhang S; Chu Y; Huang Y; Li X; Sun L; Jin N
Toxicol Appl Pharmacol; 2014 Oct; 280(2):362-9. PubMed ID: 25151223
[TBL] [Abstract][Full Text] [Related]
29. Construction of a novel oncolytic adenoviral vector and its biological characteristics.
Zhang M; Zhang X; Han Z; Chen X; Yang L; Sheng Y; Wen J
Oncol Rep; 2013 Feb; 29(2):798-804. PubMed ID: 23165979
[TBL] [Abstract][Full Text] [Related]
30. The oncolytic adenovirus targeting to TERT and RB pathway induced specific and potent anti-tumor efficacy in vitro and in vivo for hepatocellular carcinoma.
Zhang W; Cai R; Luo J; Wang Y; Cui Q; Wei X; Zhang H; Qian C
Cancer Biol Ther; 2007 Nov; 6(11):1726-32. PubMed ID: 18281783
[TBL] [Abstract][Full Text] [Related]
31. Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner.
Kim E; Kim JH; Shin HY; Lee H; Yang JM; Kim J; Sohn JH; Kim H; Yun CO
Hum Gene Ther; 2003 Oct; 14(15):1415-28. PubMed ID: 14577922
[TBL] [Abstract][Full Text] [Related]
32. Dissecting the roles of E1A and E1B in adenoviral replication and RCAd-enhanced RDAd transduction efficacy on tumor cells.
Wei F; Wang H; Chen X; Li C; Huang Q
Cancer Biol Ther; 2014 Oct; 15(10):1358-66. PubMed ID: 25019940
[TBL] [Abstract][Full Text] [Related]
33. Antitumor activities of an oncolytic adenovirus equipped with a double siRNA targeting Ki67 and hTERT in renal cancer cells.
Fang L; Cheng Q; Li W; Liu J; Li L; Xu K; Zheng J
Virus Res; 2014 Mar; 181():61-71. PubMed ID: 24463503
[TBL] [Abstract][Full Text] [Related]
34. Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor.
Cho WK; Seong YR; Lee YH; Kim MJ; Hwang KS; Yoo J; Choi S; Jung CR; Im DS
Mol Ther; 2004 Nov; 10(5):938-49. PubMed ID: 15509511
[TBL] [Abstract][Full Text] [Related]
35. Gene-viral cancer therapy using dual-regulated oncolytic adenovirus with antiangiogenesis gene for increased efficacy.
Su C; Na M; Chen J; Wang X; Liu Y; Wang W; Zhang Q; Li L; Long J; Liu X; Wu M; Fan X; Qian Q
Mol Cancer Res; 2008 Apr; 6(4):568-75. PubMed ID: 18344493
[TBL] [Abstract][Full Text] [Related]
36. A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models.
Zhang J; Lai W; Li Q; Yu Y; Jin J; Guo W; Zhou X; Liu X; Wang Y
Biochem Biophys Res Commun; 2017 Sep; 491(2):469-477. PubMed ID: 28698142
[TBL] [Abstract][Full Text] [Related]
37. New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication.
Hernandez-Alcoceba R; Pihalja M; Qian D; Clarke MF
Hum Gene Ther; 2002 Sep; 13(14):1737-50. PubMed ID: 12396626
[TBL] [Abstract][Full Text] [Related]
38. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
[TBL] [Abstract][Full Text] [Related]
39. Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-gamma gene yields efficient antitumor activity in immunodeficient and immunocompetent mice.
Su C; Peng L; Sham J; Wang X; Zhang Q; Chua D; Liu C; Cui Z; Xue H; Wu H; Yang Q; Zhang B; Liu X; Wu M; Qian Q
Mol Ther; 2006 May; 13(5):918-27. PubMed ID: 16497559
[TBL] [Abstract][Full Text] [Related]
40. Potent antitumoral effects of a novel gene-viral therapeutic system CNHK300-mEndostatin in hepatocellular carcinoma.
Li GC; Yang JM; Nie MM; Su CG; Sun LC; Qian YZ; Fang GE; Sham J; Wu MC; Qian QJ
Chin Med J (Engl); 2005 Feb; 118(3):179-85. PubMed ID: 15740644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
